Inhibiting the CXCL-CXCR2 axis with CXCR2 antagonists has been shown to inhibit tumor growth, extend survival, and induce anti-angiogenesis effects in tumor xenograft models [20,21]. This evidence concerns the gene CXCR2 and neoplasm.